skip to primary navigationskip to content

Send in your Zoom Box photos for our competition!

If you made a Zoom Box at our busy hands-on Science Festival event on Saturday 18th March, why not try it out with your own choice of specimens and submit your photos to our competition? You can enter up to 3 photos (send them by email to to be in with a chance of winning a microscope.

Competition entry rules here

New cellular mechano-sensing mechanism

Edouard Hannezo from the Simons group, with colleagues from Institut Curie, show that neighbouring cells take an active part in each cell division. By combining fly genetics and live-imaging with biophysical modelling, they have discovered a new mechanism that allows forces to be sensed and transmitted from one cell to another.

Read more

Genes that resist reprogramming by nuclear transfer

The Gurdon lab are exploring how to improve the success of nuclear reprogramming (with the ultimate aim of creating patient-specific cells for therapeutic replacement). In this paper they identify genes that are resistant to transcriptional reprogramming following nuclear transfer and show that multiple epigenetic pathways are involved.

Read more

Screening potential Alzheimer's drugs in vitro

The Livesey lab have developed an in vitro stem cell model of Alzheimer-type dementia using neurons derived from Down syndrome patient cells. They now demonstrate the feasibility of using these cells to screen small molecules that modulate production of toxic forms of the Amyloid beta protein.

Read more

Next in the Gurdon Institute Seminar Series

Coming up on Monday 10th April 2017, we welcome Ross Cagan (Icahn School of Medicine at Mount Sinai, New York, USA) to talk about ’Embracing complexity: A fly-to-bedside approach to cancer therapies’. All welcome. Note this is (unusually) on a Monday, but is still at 11.30am.

Read more

Newly released video: Meet Andrea Brand

Andrea describes her research on neural stem cells in the final instalment of our series of ten group leader videos.

Watch here

Lynparza trial shows efficacy against breast cancer

Lynparza (olaparib), the anti-cancer drug that arose from Steve Jackson's research into DNA repair, became a registered medicine for some ovarian cancers in late 2014. AstraZeneca has now reported significant positive results from a Phase III clinical trial that may pave the way for Lynparza to be prescribed in certain breast cancer cases with BRCA1/2 mutations.

Read more

Studying development to understand disease

The Gurdon Institute is funded by the Wellcome Trust and Cancer Research UK to study the biology of development, and how normal growth and maintenance go wrong in cancer and other diseases.


Share this